Editorial & Medical Safety Notice
Delta Peptides is an independent scientific reference and does not provide medical advice, clinical treatment protocols, or emergency treatment algorithms. Most compounds profiled on this site are unapproved investigational agents that have not been proven safe or effective in large-scale human clinical trials. Research-use-only labeling does not establish suitability for human administration.
1. Clinical Risk Assessment & Pre-Trial Screening Frameworks
In regulated clinical research and medical endocrinology, evaluating the safety of a peptide intervention begins prior to exposure through structured participant screening. Standardized risk-assessment frameworks, as documented in published clinical guidelines, require baseline characterization of organ function, endocrine status, and exclusion criteria before any investigational or approved peptide is administered.
Baseline Laboratory and Clinical Evaluation in Research Protocols
- Hepatic and Renal Function Panels: Comprehensive metabolic panel measuring serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and total bilirubin to verify intact renal filtration (<5 kDa peptides) and hepatic protein synthesis.
- Glycemic and Endocrine Baselines: Fasting plasma glucose, fasting insulin, hemoglobin A1c (HbA1c), thyroid panel (TSH, free T4, free T3), morning cortisol, prolactin, and age- and sex-adjusted serum IGF-1 prior to growth hormone secretagogue exposure (CJC-1295, ipamorelin, sermorelin, GHRP-6, hexarelin).
- Hematologic and Cardiovascular Screening: Complete blood count (CBC) with differential, baseline blood pressure, and 12-lead electrocardiography (ECG) to exclude arrhythmias, conduction abnormalities, or fluid-overload states.
Clinical trial safety evaluations proceed sequentially through Phase I (first-in-human safety, tolerability, and pharmacokinetics in small cohorts), Phase II (preliminary efficacy and dose-ranging in target patient populations), and Phase III (large multi-center randomized controlled trials establishing statistical risk-benefit profiles), as indexed in published clinical trial databases and peer-reviewed medical literature. When a compound has never entered Phase I or Phase II human trials (such as BPC-157 for musculoskeletal indications), its human organ-toxicity, immunogenicity, and teratogenicity profiles remain unknown.
2. Contraindications & Pharmacodynamic Drug Interactions
Contraindication criteria in peptide clinical trials and approved drug labeling are established according to the FDA drug development and approval framework, separating absolute contraindications from relative physiological precautions.
Absolute and Relative Contraindications
- Active or Suspected Malignancy: Growth hormone secretagogues (CJC-1295, ipamorelin, sermorelin, GHRP-6, hexarelin) elevate circulating GH and IGF-1, which act as mitogenic and anti-apoptotic growth factors in numerous cell types. Similarly, pro-angiogenic tissue-repair peptides (BPC-157, TB-500) upregulate VEGF and endothelial migration pathways in preclinical models. Active malignancy or a history of hormone- or growth-factor-sensitive neoplasia is an absolute exclusion criterion across clinical trials.
- Pregnancy and Lactation: Controlled human reproductive and developmental toxicology studies are absent for investigational peptides. Low-molecular-weight peptides and peptidomimetics may cross the placental barrier or partition into breast milk, making pregnancy and lactation strict contraindications.
- Uncontrolled Diabetes Mellitus & Diabetic Retinopathy: Because somatotropic stimulation antagonizes peripheral glucose uptake and promotes hepatic gluconeogenesis, uncontrolled diabetes mellitus and proliferative diabetic retinopathy are contraindications to growth hormone secretagogue exposure.
- Confirmed Hypersensitivity: Any prior systemic allergic or anaphylactoid reaction to the peptide sequence, porcine brain proteins (in the case of Cerebrolysin), or formulation excipients.
- Severe Renal Impairment & Epilepsy (Cerebrolysin): Approved non-US prescribing information for Cerebrolysin specifically contraindicates its use in severe renal failure and status epilepticus or generalized seizure disorders due to reported increases in seizure frequency.
Pharmacodynamic Drug-Drug Interactions
Although peptides are degraded by ubiquitous peptidases rather than hepatic cytochrome P450 (CYP450) enzymes, clinically important pharmacodynamic interactions occur:
- Insulin and Oral Antidiabetic Agents: Growth hormone secretagogues counteract the glucose-lowering effects of insulin, sulfonylureas, metformin, and GLP-1 receptor agonists by reducing skeletal-muscle GLUT4 translocation and increasing hepatic glucose output.
- Glucocorticoids: Concomitant systemic corticosteroid therapy inhibits somatotroph GH responsiveness and compounds the hyperglycemic and sodium-retaining effects of growth hormone secretagogues.
- Thyroid Hormones: Growth hormone elevation accelerates the peripheral conversion of thyroxine (T4) to triiodothyronine (T3) via type-1 and type-2 deiodinases, which can unmask latent central hypothyroidism or alter levothyroxine requirements in clinical studies.
- Antihypertensives and Anticoagulants: GH-induced renal sodium and water retention can oppose antihypertensive and diuretic therapy, while nitric-oxide-modulating peptides (BPC-157) have theoretical interactions with vasoactive or antiplatelet agents in animal models.
3. Adverse Event Grading, Immunogenicity & Hypersensitivity
In clinical trials, adverse events are systematically classified using the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) (see Adverse Event Literature for compound-by-compound trial data):
- Grade 1 (Mild): Asymptomatic or mild symptoms (such as transient local erythema, induration, or pruritus at a parenteral administration site, or brief facial flushing with GHRH analogues); clinical observation only.
- Grade 2 (Moderate): Minimal, local, or noninvasive intervention indicated (such as mild peripheral edema, arthralgias, or transient fasting glucose elevation).
- Grade 3 (Severe or Medically Significant): Hospitalization or prolongation of hospitalization indicated; disabling symptoms (such as severe carpal tunnel compression, marked hyperglycemia, or generalized urticaria).
- Grade 4 (Life-Threatening): Urgent medical intervention required (such as systemic anaphylaxis, angioedema with airway compromise, or acute cardiovascular events).
- Grade 5 (Death): Fatal adverse event related to exposure.
Immunogenicity, Anti-Drug Antibodies (ADAs) & Anaphylaxis
Polypeptides—particularly non-endogenous sequences, chemically modified analogues (CJC-1295 maleimide-albumin conjugates), xenogeneic tissue extracts (Cerebrolysin porcine brain digest), or aggregated and oxidized peptide species—can be recognized by antigen-presenting cells and elicit anti-drug antibodies (ADAs). Even greater risk arises when synthetic impurities or degraded aggregates act as haptens, potentially inducing neutralizing antibodies that cross-react with endogenous human hormones.
Systemic IgE-mediated hypersensitivity and anaphylaxis represent medical emergencies characterized by rapid onset of generalized urticaria, angioedema, bronchospasm, laryngeal edema, hypotension, and cardiovascular collapse. Clinical management and specialist immunology follow-up (including tryptase evaluation and skin-prick or specific IgE testing) follow established allergy and immunology clinical guidelines. In regulated clinical settings, serious and unexpected adverse events are reported to the FDA MedWatch program.
4. Analytical Chemistry Risks: SPPS Impurities, Counter-Ions & Endotoxins
A critical distinction documented by regulatory agencies is that the biological risks of an unapproved research peptide stem not only from the target molecule itself, but also from uncharacterized chemical and microbiological contaminants introduced during solid-phase peptide synthesis (SPPS) (see Supplier Compendial Compliance Audit):
- Peptidic Synthesis By-Products: Because SPPS assembles amino acids sequentially from the C-terminus to the N-terminus via iterative deprotection and coupling cycles, incomplete coupling or premature cleavage generates deletion sequences (missing one or more internal residues), insertion sequences, truncated fragments, D-amino acid diastereomers (from α-carbon racemization during coupling), and aspartimide or oxidized methionine derivatives. These closely related peptidic impurities can act as partial agonists, receptor antagonists, or immunogenic neo-epitopes.
- Trifluoroacetic Acid (TFA) Counter-Ions and Cleavage Scavengers: Standard Fmoc-SPPS utilizes concentrated trifluoroacetic acid to cleave the completed peptide from the solid resin and remove acid-labile side-chain protecting groups. Unless an explicit ion-exchange step converts the product to an acetate or hydrochloride salt, the lyophilized powder remains a TFA salt. Residual TFA and cleavage scavengers (such as triisopropylsilane or ethanedithiol) alter solution pH and exhibit cytotoxicity in mammalian cell culture assays.
- Bacterial Endotoxins (Lipopolysaccharides, LPS): Standard reversed-phase HPLC (RP-HPLC-UV) and mass spectrometry (LC-MS) are completely blind to bacterial endotoxins shed from Gram-negative cell walls during non-sterile synthesis or lyophilization. Parenteral introduction of endotoxin activates Toll-like receptor 4 (TLR4) on monocytes and macrophages, triggering an acute pyrogenic cytokine cascade (IL-1β, IL-6, TNF-α), fever, endothelial leakage, and endotoxic shock. Compendial injectable standards therefore require quantitative endotoxin testing under USP <85> (Limulus Amebocyte Lysate [LAL] or recombinant Factor C assay) and sterility testing under USP <71>.
5. United States FDA Regulatory Status (503A / 503B Bulk Substances)
In the United States, the FDA regulatory database governs both approved pharmaceutical drugs and the bulk drug substances that may be used in pharmacy compounding under Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.
Under Section 503A, a bulk drug substance may only be compounded by a state-licensed pharmacy if it: (1) is a component of an FDA-approved drug product; (2) has an applicable United States Pharmacopeia (USP) or National Formulary (NF) monograph; or (3) appears on the FDA's 503A positive bulks list. Substances nominated for evaluation on the interim 503A or 503B bulk drug substance lists were placed into Category 1 (under evaluation), Category 2 (significant safety risks identified; remaining entries include ipamorelin acetate, GHRP-2, GHRP-6 and kisspeptin-10), or Category 3 (insufficient supporting data).
FDA's page current as of April 22, 2026 lists AOD-9604, BPC-157, CJC-1295, epitalon, GHK-Cu for injectable routes, and TB-500 as nominated but withdrawn. Withdrawal is not FDA approval or clearance. GHRP-6 remains in Category 2 (503B). Ipamorelin acetate remains in Category 2 (503B) and also appears in the withdrawn nominations table.
| Compound | US FDA Marketing Approval Status | FDA 503A / 503B Bulk Drug Substance Status (Current as of April 22, 2026) |
|---|---|---|
| AOD-9604 | Unapproved investigational compound | Listed as nominated for Category 2 (503A) but nomination withdrawn. Withdrawal is not FDA approval or clearance; lacks USP/NF monograph and FDA approval. |
| BPC-157 | Unapproved investigational compound | Listed as nominated for Category 2 (503A/503B) but nomination withdrawn. Withdrawal is not FDA approval or clearance; lacks USP/NF monograph and FDA approval. |
| CJC-1295 | Unapproved investigational compound | Listed as nominated for Category 2 (503A) but nomination withdrawn. Withdrawal is not FDA approval or clearance; lacks USP/NF monograph and FDA approval. |
| Epithalon (Epitalon) | Unapproved investigational compound | Listed as nominated for Category 2 (503A) but nomination withdrawn. Withdrawal is not FDA approval or clearance; lacks USP/NF monograph and FDA approval. |
| GHK-Cu | Unapproved as a drug (used in topical cosmetics) | For injectable routes, listed as nominated for Category 2 (503A) but nomination withdrawn. Withdrawal is not FDA approval or clearance. |
| TB-500 | Unapproved investigational compound | Listed as nominated for Category 2 (503A/503B) but nomination withdrawn. Withdrawal is not FDA approval or clearance; distinct from full-length Thymosin Beta-4. |
| Ipamorelin (Acetate) | Unapproved investigational compound | Remains in Category 2 (503B) and also appears in the withdrawn nominations table. Lacks FDA approval and USP/NF monograph. |
| GHRP-6 | Unapproved investigational compound | Remains in Category 2 (503B) as a bulk substance presenting significant safety risks. |
| Hexarelin | Unapproved investigational compound | Not listed on FDA 503A or 503B positive compounding lists; lacks FDA approval and USP/NF monograph. |
| Sermorelin (Acetate) | Previously FDA-approved (Geref; discontinued for commercial reasons, not safety or efficacy) | Component of a previously FDA-approved human drug product; subject to standard prescription compounding regulations. |
| Cerebrolysin | Unapproved in the United States (approved prescription biologic in select European and Asian countries) | Porcine brain-derived biological product; not eligible for US 503A/503B pharmacy compounding. |
6. World Anti-Doping Agency (WADA) Prohibited List Status
For competitive athletes governed by the World Anti-Doping Code, the WADA Prohibited List classifies virtually all systemic growth hormone secretagogues and regenerative peptides as prohibited at all times (both in-competition and out-of-competition):
- Class S0 (Non-Approved Substances): Any pharmacological substance not addressed by another section of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (encompassing unapproved experimental peptides such as AOD-9604 and epithalon).
- Class S2.2.1 & S2.2.2 (Growth Hormone, GHRH Analogues, and GH Secretagogues): Explicitly prohibits growth hormone fragments (AOD-9604), GHRH analogues (CJC-1295, sermorelin), and growth hormone secretagogues/GHRPs (ipamorelin, GHRP-6, hexarelin).
- Class S2.2.4 & S2.3 (Growth Factors and Growth Factor Modulators): Explicitly prohibits BPC-157, Thymosin-β4 and its derivatives including TB-500, and growth factor modulators affecting tendon, ligament, muscle, or vascular remodeling.
7. Regulatory & Literature References
- published clinical guidelines
- U.S. Food and Drug Administration. The FDA Drug Development and Approval Process: Contraindications, Warnings, and Precautions. fda.gov/drugs/development-approval-process-drugs.
- U.S. Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. fda.gov/safety/medwatch.
- National Institutes of Health. ClinicalTrials.gov Registry of Phase I–III Human Clinical Trials. clinicaltrials.gov.
- National Center for Biotechnology Information. Peer-Reviewed Medical Literature and Peptide Safety Reviews. ncbi.nlm.nih.gov/pubmed.
- American Academy of Allergy, Asthma & Immunology (AAAAI). Anaphylaxis Recognition, Clinical Management, and Specialist Immunology Follow-Up Guidelines. aaaai.org/conditions-treatments/allergies/anaphylaxis.
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Sections 503A and 503B of the FD&C Act (current as of April 22, 2026). fda.gov.